As discussed throughout this article, the therapeutic approach to HER2-positive breast cancer in older patients must be carefully personalized, considering the diversity of physical conditions, comorbidities, treatment tolerance and the patient’s preferences regarding their quality of life (Fig. 1). This evidence concerns the gene ERBB2 and breast cancer.